Atara Biotherapeutics Inc.

Atara Biotherapeutics develops T‑cell immunotherapies, with lead product Tab‑cel in Phase 3 for EBV‑driven post‑transplant disease; it also pursues CAR T for blood and solid tumors in partnership with MSLK, QIMR, and Bayer.

Headquarters: United States (USA)

Atara Biotherapeutics Inc. Logo
Company Profile
  • Employees: 38
  • HQ: Thousand Oaks
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
ATRA Atara Biotherapeutics Inc.
Cap: 0.1B | P/E: 5.2
EQUITY NMS USD US0465131078 Active
📈
Home Login